H.C. Wainwright analyst Michael King maintained a Buy rating on Regeneron (NASDAQ:REGN) on Tuesday, setting a price target of $703, which is approximately 21.67% above the present share price of $577.78.
King expects Regeneron to post earnings per share (EPS) of $10.58 for the third quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Regeneron, with an average price target of $654.08.
The analysts price targets range from a high of $814 to a low of $495.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $2.53 billion and a net profit of $1.11 billion. The company's market cap is $61.56 billion.
According to TipRanks.com, H.C. Wainwright analyst Michael King is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.6% and a 55.88% success rate.
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.